Analyst Price Targets — IOVA
Latest News for IOVA
Corient Private Wealth LP purchased a new stake in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 55,275 shares of the biotechnology company's stock, valued at approximately $230,000. Other hedge funds have also modified their holdings
Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports…
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO),…
Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IOVA.
U.S. House Trading
No House trades found for IOVA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.